Chad Tang, Radiation Oncologist at the MD Anderson Cancer Center, shared a post on X about a paper he co-authored with colleagues published in The Lancet Oncology:
“Excited to share our recent Lancet Oncology publication on sequential SBRT for oligometastatic clear cell RCC. Our outcomes show excellent outcomes in 121 patients with 1-5 metastases.
This phase II expansion cohort came on the heels of our original 2021 manuscript demonstrating the feasibility of SBRT alone. We expanded our trial and pre-specified a 2-year systemic therapy survival as our threshold for success.
After a median of 3 years of follow-up. The median systemic therapy-free survival was 34 months, exceeding our threshold for success. PFS was promising as well, with a median of 17.7 months.
We looked at ctDNA using the myriad 2nd-generation assays and found 60% of patients to exhibit molecular residual disease. Furthermore, this marker was highly prognostic both before and after radiation therapy.
So, med oncologists, I know we need randomized phase 3 data, but hopefully we can consider this treatment for low-volume patients.”
JeeSuk Chang, Radiation Oncologist and Associate Professor at Yonsei Cancer Center, shared this post, adding:
“Pay attention to this part: A second round of metastasis-directed therapy was administered to 71 (59%) of 121 patients, with up to six rounds of metastasis-directed therapy given.”
Title: Metastasis-directed radiotherapy without systemic therapy for oligometastatic clear-cell renal-cell carcinoma: primary efficacy analysis of a single-arm, single-centre, phase 2 trial
Authors: Chad Tang, Alexander D. Sherry, Aaron Seo, Kieko Hara, Haesun Choi, Suyu Liu, Xiaowen Sun, Anya Montoya, Ethan B. Ludmir, Amishi Y. Shah, Eric Jonasch, Amado J. Zurita, Craig Kovitz, Omar Alhalabi, Sangeeta Goswami, Andrew W. Hahn, Matthew T. Campbell, Arianna Hernandez, Kevin T. Nead, Peter Van Loo, Pavlos Msaouel
Read The Full Article at The Lancet Oncology.
More Posts Featuring Renal Cell Carcinoma.